[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-inflammatory-hyperpigmentation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-inflammatory-hyperpigmentation":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645197","a-clinical-study-to-evaluate-the-efficacy-in-improving-dark-spots-after-8-weeks-of-use-of-facial-sunscreens-in-adult-participants-100645197",false,"NCT07679945","A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants","A Monocentric and Open-Label Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Research Participants","El Porto Ex-US","Inclusion Criteria:\n\n1. Able to understand and follow study instructions\n2. Fitzpatrick skin types I-VI\n3. Presence of facial hyperpigmentation, such as:\n\n   * Mild to moderate melasma, or\n   * Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation)\n4. Willing to comply with study procedures and product use\n5. For subjects in applicable groups: willing to use assigned sunscreen product\n\nExclusion Criteria:\n\n1. Known sensitivity or allergy to cosmetic or skincare products\n2. Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring)\n3. Use of medications or products that may interfere with study evaluations\n4. Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures)\n5. Excessive sun exposure or use of tanning beds immediately prior to or during the study\n6. Pregnancy or intention to become pregnant during the study\n7. Participation in another clinical study within a recent period\n8. Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results",true,"ALL","18 Years",{"count":21,"type":22},152,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines\u002Fpost-inflammatory hyperpigmentation) after 8 weeks of product use under normal conditions by adult participants.",[28,29,30],"Post-inflammatory Hyperpigmentation","Melasma","Solar Lentigo","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-02",{"date":39,"type":22},"2026-09-25",{"name":41,"class":42},"Kenvue Brands LLC","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100639880","study-on-the-functional-impact-of-cosmetics-on-improving-self-esteem-and-quality-of-life-in-black-women-100639880","NCT07618572","Study on the Functional Impact of Cosmetics on Improving Self-Esteem and Quality of Life in Black Women","Inclusion Criteria:\n\n* Female participants aged 18 to 55 years\n* Clinical diagnosis of facial post-inflammatory hyperpigmentation (PIH)\n* Self-identified as Black (including \"preta\" or \"parda\")\n* Fitzpatrick skin types IV to VI\n* Employees, students, or affiliated personnel of Hospital Israelita Albert Einstein (including contractors and fellows), recruited from institution units\n* Willing and able to comply with all study procedures and attend all scheduled visits\n* Able and willing to provide written informed consent and authorization for image use\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or those planning pregnancy during the study period\n* Type 1 diabetes mellitus or related complications (e.g., nephropathy, dermatological conditions associated with diabetes, history of hypoglycemia, diabetic ketoacidosis, or hyperosmolar coma)\n* Known or suspected intolerance to similar cosmetic products\n* History of atopy or allergic reactions to cosmetic products\n* Personal or family history of skin cancer\n* Active skin conditions or lesions affecting the face\n* Facial marks or scars that may interfere with assessments\n* Skin irritation due to recent sun exposure\n* Excessive sun or UV exposure, including artificial tanning, within the past month\n* Use of facial cosmetic products within 7 days before screening\n* Use of topical or systemic treatments within 1 month before screening\n* Use of depigmentation treatments within 3 months before screening\n* Use of dermocosmetic treatments for PIH within 3 months before screening\n* Facial dermatological or aesthetic procedures within 2 weeks before screening\n* Use of corticosteroids, anticoagulants, or immunosuppressive drugs\n* Score ≥5 indicating anxiety or depression on Patient Health Questionnaire (PHQ-9) or Generalized Anxiety Disorder scale (GAD-7)\n* Any other condition that, in the investigator's judgment, may compromise study participation or results (to be documented in the medical record)","FEMALE","55 Years",{"count":53,"type":22},60,[25],"The goal of this clinical trial is to evaluate whether the use of dermocosmetics containing Bioceramides and Niacinamide can improve post-inflammatory hyperpigmentation and promote positive impacts on self-esteem and quality of life in Brazilian Black women with facial hyperpigmentation (Fitzpatrick skin types IV to VI).\n\nThe main questions it aims to answer are:\n\n* Does the treatment improve hyperpigmentation severity as measured by HASI and IGA scores?\n* Does the treatment improve participants' self-esteem and quality of life as assessed by MELASQoL and DLQI questionnaires?\n\nParticipants will:\n\n* Use a standardized skincare routine including cleanser (0.2% Bioceramides), moisturizer (2% Niacinamide + 1% Bioceramides), serum (5% Niacinamide + 3% Bioceramides), and SPF 30 sunscreen for 12 weeks.\n* Attend study visits at baseline, week 6, and week 12.\n* Undergo standardized facial photography and clinical assessments by specialists at baseline, week 6, and week 12.\n* Complete questionnaires related to self-esteem and quality of life at baseline, week 6, and week 12.",[28],[28,58,59,60,61],"Bioceramides","Niacinamide","Black Women","Facial Hyperpigmentation",{"date":63,"type":35},"2026-06-04",{"date":65,"type":35},"2026-03-19",{"date":67,"type":22},"2026-10-31",{"name":69,"class":70},"Hospital Israelita Albert Einstein","OTHER","Post Inflammatory Hyperpigmentation"]